KPTI

SEC source: 0001209191-22-027344 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 661,317

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-026425 · doc4.xml · derivative · entry 2

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-04-28

F2 · derivative.exercise_date: This option was granted on April 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on April 29, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-026425 · doc4.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning April 29, 2023.

SEC source: 0001209191-22-021755 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2032-03-28

F2 · derivative.exercise_date: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-021755 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 958,131

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014622 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires 2032-02-27

F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014622 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,500

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014621 · doc4.xml · derivative · entry 2

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2032-02-27

F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014621 · doc4.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014619 · doc4.xml · derivative · entry 2

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2032-02-27

F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014619 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 661,950

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014624 · doc4.xml · derivative · entry 4

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-02-27

F5 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 3

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 898,131

F4 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 713,757

F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014624 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719,983

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014629 · doc4.xml · derivative · entry 3

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2032-02-27

F4 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014629 · doc4.xml · nonDerivative · entry 2

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,290

F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014629 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,953

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014628 · doc4.xml · derivative · entry 3

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,600

Underlying: Common Stock · 111,600 shares

Expires 2032-02-27

F4 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014628 · doc4.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,110

F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014628 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,508

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014626 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-02-27

F5 · derivative.exercise_date: This option was granted to the spouse of the reporting person on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 713,757

F4 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 719,983

F3 · shares: Represents the award of restricted stock units ("RSUs") to the spouse of the reporting person pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-014626 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 898,131

F1 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014623 · doc4.xml · derivative · entry 2

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,400

Underlying: Common Stock · 59,400 shares

Expires 2032-02-27

F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-014623 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,546

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.

SEC source: 0001209191-22-011636 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 904,357

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011636 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,983

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011650 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,450

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011643 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,703

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011639 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 698,983

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-011639 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904,357

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008124 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 913,445

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008124 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 708,062

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008130 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,756

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

F3 · balance_after: Includes 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021.

SEC source: 0001209191-22-008128 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,632

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

F3 · balance_after: Includes 861 shares and 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021 and October 31, 2021, respectively.

SEC source: 0001209191-22-008126 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,308

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008119 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 708,062

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-22-008119 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 913,445

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-21-068261 · doc4.xml · derivative · entry 1

Honig Peter · CIK 0001484780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,800

Underlying: Common Stock · 47,800 shares

Expires 2031-12-02

F1 · derivative.exercise_date: This option was granted on December 3, 2021. The shares underlying the option vest as to one-third (1/3) of the shares on December 3, 2022 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter.

SEC source: 0001209191-21-067954 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,296

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary sale by the reporting person.

F2 · balance_after: Includes 1,323 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021.

SEC source: 0001209191-21-046589 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,137

F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligation in connection with the vesting of 2,413 restricted stock units on July 11, 2021.

SEC source: 0001209191-21-044423 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · SVP Sales & Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-06-29

F2 · derivative.exercise_date: This option was granted on June 30, 2021. The shares underlying this option vest as to 25% of the shares on June 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-044423 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · SVP Sales & Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on June 7, 2022, the first anniversary of Ms. Cheng's date of hire, with the remaining 50% vesting on June 7, 2023.

SEC source: 0000899243-21-021767 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,472

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-021368 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-31

F2 · derivative.exercise_date: This option was granted on June 1, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on June 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-21-021368 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,255

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning June 1, 2022.

SEC source: 0000899243-21-021292 · doc4.xml · derivative · entry 2

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock · 1,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On November 30, 2020, the reporting person was granted 3,000 RSUs, which vested as to 50% of the shares on May 30, 2021, with the remaining 50% vesting on November 30, 2021. 1,500 of the RSUs vested on May 30, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On November 30, 2020, the reporting person was granted 3,000 RSUs, which vested as to 50% of the shares on May 30, 2021, with the remaining 50% vesting on November 30, 2021. 1,500 of the RSUs vested on May 30, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0000899243-21-021292 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · balance_after: The reporting person has reported a prior award of 3,000 RSUs (described in footnote 3 below) in Table II of Form 4. The total reported in Column 5 includes 1,500 RSUs previously reported in Table II and 1,500 shares of common stock.